Quantcast

Latest Tolerx Stories

2014-08-05 08:34:27

Supports progression of this first-in-class anti-TLR4 monoclonal antibody into clinical proof of concept study as a potential personalized medicine for rheumatoid arthritis GENEVA, August 5, 2014 /PRNewswire/ -- Novimmune SA, a company focused on the discovery and development of antibody-based drugs to benefit patients with inflammatory, auto-immune disorders, and cancer announces today the completion of a comprehensive Phase I clinical trial investigating the pharmacokinetics,...

2014-07-15 08:28:23

MONROVIA, Calif., July 15, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced the appointment of Kurt Gustafson to its board of directors. Mr. Gustafson will also serve as chair of Xencor's audit committee and as a member of the compensation committee. Xencor also announced the promotion of John R....

2014-02-12 08:28:24

Clinical program focused on reversing type 1 diabetes symptoms in patients diagnosed within six months of trial initiation EDGEWATER, N.J. and SAN DIEGO, Feb. 12, 2014 /PRNewswire/ -- DiaVacs, Inc., a clinical stage biotechnology company focused on developing cell-based therapy for treatment of type 1 diabetes, and Profil(® )Institute for Clinical Research, Inc., an early phase clinical research organization focused on diabetes and obesity, announced today a strategic collaboration...

2011-06-23 06:00:00

ROCKVILLE, Md., June 23, 2011 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that 1-year data from Protege, the Company's Phase 3 clinical study of teplizumab in type 1 diabetes patients, will be presented at the American Diabetes Association's 71st Scientific Sessions symposium in San Diego, California on June 28, 2011 at 9:10 a.m. PDT. Dr. Nicole...

2011-06-14 04:00:00

TAIPEI, Taiwan, June 14, 2011 /PRNewswire-Asia/ -- TWi Biotechnology Inc. announced today that the company has enrolled over 50% of the total 240 patients for the Phase IIb clinical trial of AC-201 for the treatment of Type II Diabetes. The randomized, double-blind, placebo-controlled, dose-ranging, multi-center study is primarily designed to evaluate the glycated hemoglglobin A1c (HbA1c) lowering effects of AC-201 in patients with Type II Diabetes Mellitus. Meanwhile, the cardiovascular...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.